---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-045112"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:23:45.405556+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bioventus Q3 revenue up 15% to $139M; raises FY2024 guidance midpoint

## Summary
- Q3 revenue $139.0M (+15.0% YoY); net loss improved to $5.4M from $8.8M; Adjusted EBITDA $23.6M (+8.4%).
- Non-GAAP EPS $0.06 vs $0.05; GAAP loss per share $0.07 vs $0.12.
- Pain Treatments +16.7%, Surgical Solutions +18.5%, Restorative Therapies +1.2% (all YoY).
- Agreed to divest Advanced Rehabilitation Business for up to $45M; close expected late 2024/early 2025; proceeds to reduce debt.
- FY2024 guidance: net sales $562-567M, Adj. EBITDA $104-107M, Non-GAAP EPS $0.40-0.42 (midpoints raised).

## SEC filing metadata
- accession: 0001628280-24-045112
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828024045112/0001628280-24-045112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828024045112/bvs-20241105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-045112
- JSON: https://secwatch.observer/filing/0001628280-24-045112.json
- Plain text: https://secwatch.observer/filing/0001628280-24-045112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.